Abstract
Background
Prior work showed that patients from the CorEvitas Psoriasis Registry who had previously failed a prior biologic and then initiated ixekizumab demonstrated improvements in disease severity and patient-reported outcomes after 6 months. However, newer therapies such as interleukin-23 inhibitors (IL-23i) were not considered. Here, with more recent data including IL-23i, 6-month effectiveness of ixekizumab following a switch from any biologic was assessed as well as whether 6-month effectiveness of ixekizumab was impacted by prior biologic class.
Methods
We included CorEvitas Psoriasis Registry patients who initiated ixekizumab after discontinuing another biologic therapy and had a corresponding 6-month follow-up visit following ixekizumab initiation (N = 743, 2016–2023). Immediate prior biologic class was categorized as tumor necrosis factor inhibitor (TNFi) or interleukin-12/23 inhibitors (IL-12/23i, n = 405), non-ixekizumab interleukin-17i (IL-17i, n = 237), or IL-23i (n = 101). Adjusted mean changes in body surface area (BSA), Dermatology Life Quality Index (DLQI), itch, and skin pain were calculated for prior biologic class groups using analysis of covariance (ANCOVA). Proportions achieving ≥ 75%, ≥ 90%, and ≥ 100% improvement in Psoriasis Area and Severity Index (PASI75, PASI90, and PASI100, respectively), Investigator’s Global Assessment (IGA) 0/1, and DLQI 0/1 were calculated for all patients and compared among prior biologic classes via relative risks (RRs) and 95% confidence intervals (CIs) using multivariable modified Poisson regression.
Results
Mean improvements in BSA, DLQI, itch, and skin pain, were 7.6, 3.6, 23.3, and 16.7, respectively, for ixekizumab patients who switched from TNFi or IL-12/23i (all p < 0.05); 6.8, 3.3, 19.6, and 14.1, respectively, for those who switched from non-ixekizumab IL-17i (all p < 0.05); and 7.8, 3.4, 22.2, and 12.8, respectively, for those who switched from IL-23i (all p < 0.05). Overall, 54%, 41%, and 31% of ixekizumab initiators achieved PASI75, PASI90, and PASI100, respectively, 50% maintained or achieved IGA 0/1, and 48% maintained or achieved DLQI 0/1. The prior TNFi or IL-12/23i group was 31% more likely to achieve PASI100 (RR = 1.31, 95% CI 1.01, 1.69) and 32% more likely to maintain or achieve IGA 0/1 (RR = 1.32, 95% CI 1.11, 1.57), but not significantly more likely to achieve PASI90. The prior IL-23i group was 45% more likely to achieve PASI90 (RR = 1.45, 95% CI 1.10, 1.91), 55% more likely to achieve PASI100 (RR = 1.55, 95% CI 1.12, 2.13), and 39% more likely to maintain or achieve IGA 0/1 (RR = 1.39, 95% CI 1.12, 1.73) compared to the prior non-ixekizumab IL-17i group. Achievement of PASI75 and DLQI 0/1 was consistent across the prior TNFi or IL-12/23i, IL-23i, and non-ixekizumab IL-17i groups.
Conclusions
These updated findings with IL-23i data reaffirm that patients with psoriasis who switch to ixekizumab after discontinuing another biologic demonstrate improvement in disease severity and patient-reported outcomes at 6 months in real-world settings. Compared to patients who switched from another IL-17i, patients who switched class from a TNFi or IL-12/23i were more likely to achieve PASI100 and IGA 0/1, and patients who switched class from an IL-23i were more likely to achieve PASI90 in addition to PASI100 and IGA 0/1.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Real-world patients with psoriasis who switch to ixekizumab after discontinuing another biologic show improvements in disease severity and patient-reported outcomes at 6 months. |
These improvements were largely similar irrespective of the immediate prior biologic class; however, patients who switched class (from a TNFi or IL-12/23i, or IL-23i) were more likely to achieve response for some disease severity outcomes compared to patients who switched from a prior IL-17i. |
1 Introduction
Biologic therapies have made an important contribution in treating psoriasis in the last two decades. These include tumor necrosis factor inhibitors (TNFi), the biologic class approved first, along with newer therapeutic classes such as interleukin-17a inhibitors (IL-17i), interleukin-12/23 inhibitors (IL-12/23i), and interleukin-23 inhibitors (IL-23i). With the increasing number of available biologic therapies, patient switching between biologic therapies (within therapeutic class or to another class) is becoming a common practice and may be due to several factors, including treatment failure, adverse events, economic factors, and patient preferences [1,2,3]. Not all switches, however, lead to improved outcomes [1]. Due to lack of strong evidence, there are no specific US guideline recommendations for switching biologic treatments [1]. More data from real-world sources are needed to fill this evidence gap.
Many studies have reported similar effectiveness of ixekizumab, an IL-17i, between biologic-experienced and biologic-naïve patients [4,5,6], whereas few studies have examined the effectiveness of ixekizumab following a switch from an IL-23i. Mastorino et al. found that out of 769 patients, seven patients switched to an IL-17i after treatment failure with an IL-23i [7]. They reported a rapid response in all patients and that five of the seven achieved ≥ 100% improvement in the Psoriasis Area Severity Index (PASI100) at 28 weeks.
We previously conducted a study of 419 patients enrolled through September 2020 in the CorEvitas Psoriasis Registry to compare the effectiveness of ixekizumab between patients who previously failed secukinumab (within class; another IL-17i) and those who failed other biologics (composite of TNFi, IL-12/23i, and IL-23i) [8]. All patients who initiated ixekizumab demonstrated improvements in measures of disease severity and patient-reported outcomes after 6 months. We also found that those who switched from secukinumab demonstrated fewer improvements than patients who switched from other biologic therapies. Due to limited sample size, we were unable to compare patients switching from an IL-23i specifically or from the IL-17 receptor blocker brodalumab.
Since September 2020, increasing numbers of patients initiating newer biologic therapies within the CorEvitas Psoriasis Registry and additional patient follow-up have facilitated examination of the effectiveness of ixekizumab after a switch from an IL-23i. Furthermore, while prior real-world studies have identified several factors that impact response to biologic therapy, including sex, employment status, smoking, weight, psoriasis in high-impact sites, and disease activity at biologic initiation [9, 10], it is unclear whether these factors influence ixekizumab effectiveness after switching from other biologic therapies. To add to the growing data surrounding switching of biologic therapies, the objective of this analysis was to determine whether 6-month effectiveness of ixekizumab is impacted by prior biologic class, by stratifying our results into three groups of prior biologic class (TNFi or IL-12/23i, IL-17i [excluding ixekizumab], and IL-23i). In addition, we sought to examine factors impacting 6-month effectiveness following any biologic switch.
2 Methods
2.1 Description of the CorEvitas Psoriasis Registry
The CorEvitas Psoriasis Registry is a prospective, multicenter, non-interventional registry, launched in April 2015 in collaboration with the National Psoriasis Foundation, for patients with psoriasis under the care of a dermatologist. The registry design has been previously described [11]. Patients were enrolled if they were 18 years or older, had psoriasis diagnosed by a dermatologist, and initiated or switched to a US Food and Drug Administration (FDA)-approved systemic or biologic psoriasis treatment at registry enrollment or within 12 months before enrollment.
Data are collected from dermatologists and patients during routine clinical visits occurring at approximately 6-month intervals. All participating investigators were required to obtain full board approval for conducting research involving human subjects. All registry subjects were required to provide written informed consent prior to participating.
2.2 Study Population
The current study included patients who switched to ixekizumab after discontinuing another biologic therapy at or after enrollment into the registry (baseline visit) beginning on 22 March 2016, the approval date of ixekizumab. Further, included patients were required to have a corresponding 6-month follow-up visit (within a 5- to 9-month window) as of February 2023. Biologic-naïve patients initiating ixekizumab were excluded.
2.3 Measures
2.3.1 Prior Biologic Class
Patients were classified into one of three mutually exclusive groups based on their immediate prior biologic class: (1) TNFi (adalimumab, certolizumab, etanercept, infliximab, golimumab) or IL-12/23i (ustekinumab); (2) non-ixekizumab IL-17i (secukinumab, brodalumab); and (3) IL-23i (guselkumab, tildrakizumab, risankizumab). No patients with prior bimekizumab were included.
2.3.2 Outcomes
Disease activity measures: Psoriasis Area and Severity Index (PASI) [12], body surface area (BSA) [13], and Investigator’s Global Assessment (IGA) [14] were measured at the baseline and 6-month follow-up visits, and mean changes from baseline were calculated at follow-up. Also at follow-up, the proportions of patients achieving ≥ 75% improvement in PASI (PASI75), ≥ 90% improvement in PASI (PASI90), and ≥ 100% improvement in PASI (PASI100) were ascertained. In addition, the proportions of patients maintaining or achieving PASI ≤ 3, acceptable response (BSA ≤ 3% or BSA improvement ≥ 75% from baseline) or target response (BSA ≤ 1%) [15], and IGA 0/1 [14] at follow-up were determined.
Patient-reported outcomes: At the baseline and follow-up visits, skin itch/pruritus, skin pain, fatigue, and current health status (EQ-5D-3L) were measured using visual analog scales (VAS, 0-100) in all patients, and, in patients with comorbid psoriatic arthritis, joint pain due to psoriatic arthritis and Patient Global Assessment (PGA) were measured using a visual analog scale (VAS; 0–100) [16]. Lower scores indicate better health for itch, skin and joint pain, fatigue, and PGA, while higher scores indicate better health for EQ-5D-3L. Mean changes in these scores and in Dermatology Life Quality Index (DLQI) [17] were calculated from baseline to follow-up. Additionally, proportions of patients maintaining or achieving DLQI 0/1 at follow-up were determined [18].
2.3.3 Covariates
Baseline visit variables included sociodemographics, lifestyle characteristics, comorbidity burden, psoriasis disease characteristics, and psoriasis-specific measures. Medications included past and concomitant psoriasis therapies (non-biologic systemics (apremilast, methotrexate, cyclosporine, acitretin), phototherapy and topical agents, and previous biologic therapies, including the number of prior biologics (categorized as 0, 1, or ≥ 2)).
2.4 Statistical Analysis
Patient characteristics and disease severity measures at the baseline visit were summarized using descriptive statistics stratified by prior biologic class. Summary measures for continuous variables included number of observations, means, standard deviations (SDs), medians, and 25th and 75th percentiles, while categorical variables were summarized using frequency counts and percentages. Baseline differences in means or proportions of characteristics between prior biologic class groups were calculated using Cohen’s f (for continuous variables) and Cohen’s w (for categorical variables), each a type of standardized effect size that assesses global imbalance among all groups (i.e., any difference in characteristic between two prior biologic class groups). Thresholds for small, medium, and large differences were, respectively, 0.10, 0.25, and 0.40 for Cohen’s f, and 0.10, 0.30, and 0.50 for Cohen’s w.
For each continuous outcome, an analysis of covariance (ANCOVA) model was used to calculate and compare unadjusted and multivariable-adjusted mean absolute change in continuous outcomes at 6 months within and between prior biologic class groups. For each dichotomous outcome, disease response at 6 months was summarized by prior biologic class using frequencies and percentages. Modified Poisson regression models with robust standard errors were fit to calculate the relative risk (RR) and 95% confidence intervals (CIs) to estimate the likelihood of response by prior biologic class relative to non-ixekizumab IL-17i group for response outcomes. Modified Poisson regression allows for direct estimation of the RR and applies the robust error variance to correctly estimate CIs [19]. All models were adjusted a priori for age, gender, race, duration of psoriasis, psoriatic arthritis, number of prior biologics, and baseline outcome measure. Additional patient characteristics were reviewed for potential inclusion in the models; none demonstrated at least a moderate difference between strata with ≤ 5% missing values, and therefore none were added to the models. No adjustments were made for multiple comparisons in this study. A p-value < 0.05 was considered statistically significant.
In a secondary analysis, factors likely to be associated with a disease activity outcome (achieving PASI75) and a patient-reported outcome (maintaining or achieving DLQI 0/1) were evaluated in separate univariable analyses for each factor using modified Poisson regression with robust standard errors. Factors with p-value ≤ 0.10 in the univariable models and ≤ 5% missing values were included in a multivariable modified Poisson regression model for each outcome and removed individually via backward selection until all remaining variables were significant (p < 0.05). Stata version 16.1 (StataCorp, LLC, College Station, TX, USA) was used for all analyses.
2.5 Ethics
The study was performed in accordance with the Declaration of Helsinki and the Guidelines for Good Pharmacoepidemiology Practice (GPP). All participating investigators were required to obtain full board approval for conducting non-interventional research involving human subjects with a limited dataset. Sponsor approval and continuing review was obtained through a central Institutional Review Board (IRB, Advarra, Protocol number Pro00051221). For academic investigative sites that did not receive a waiver to use the central IRB, full board approval was obtained from the respective governing IRBs and documentation of approval was submitted to CorEvitas, LLC, prior to the initiation of any study procedures. All patients in the registry were required to provide written informed consent and authorization prior to participating.
3 Results
3.1 Patient Characteristics
As of 10 February 2023, among the 18,556 patients enrolled in the Psoriasis Registry, there were 2689 initiations of ixekizumab, of which 1948 were among biologic experienced patients. Among these initiations, 1516 had a baseline visit and 743 had a 6-months follow-up visit after initiation of ixekizumab. Therefore, a total of 743 patients were included in the analysis and stratified by their immediate prior biologic class with 405 (54.5%) in the TNFi or IL-12/23i group, 237 (31.9%) in the non-ixekizumab IL-17i group, and 101 (13.6%) in the IL-23i group. The patient flowchart is shown in Fig. 1.
Patient demographic and clinical characteristics for the overall study cohort are summarized in Table 1. Patients reported a mean age of 51.0 years (SD 13.4 years) and were 51% female, 79% White, and 7% of Hispanic or Latino ethnicity. There were similarities in patient demographics, lifestyle characteristics, comorbidity burden, and psoriasis disease characteristics. Psoriasis disease severity was slightly higher among patients initiating ixekizumab who previously discontinued TNFi or IL-12/23i compared to patients in the prior non-ixekizumab IL-17i and IL-23i groups with mean BSA of 12.5% (SD 15.4) versus 10.8% (SD 14.6) and 9.0% (SD 11.6), mean PASI of 8.2 (SD 8.0) versus 7.0 (SD 8.1) and 5.6 (SD 5.7), and mean IGA of 2.8 (SD 0.9) versus 2.5 (SD 1.1) and 2.6 (SD 1.1), respectively. Patient-reported outcome measures at baseline were similar across prior biologic groups.
Treatment characteristics at baseline visit are shown in Supplemental Table 1 (Online Supplemental Material (OSM)). The duration between prior biologic discontinuation and initiation of ixekizumab was longer among patients who previously discontinued TNFi or IL-12/23i compared to patients who previously discontinued non-ixekizumab IL-17i and IL-23i. Larger proportions of patients who switched to ixekizumab from either another IL-17i or an IL-23i had received two or more prior biologics compared with patients who switched to ixekizumab from a TNFi or IL-12/23i. Among patients with baseline reporting of the reasons for discontinuing their prior biologic, the prior non-ixekizumab 17i group had a lower proportion of discontinuation due to primary non-response (inadequate initial response) compared to the prior TNFi or IL-12/23i and IL-23i groups. Similar proportions were observed for secondary non-response (failure to maintain initial response), lack of effectiveness, patient doing well, and contraindications across groups.
3.2 Six-Month Outcomes Overall
Mean absolute changes in continuous disease activity and patient-reported outcomes from baseline to 6 months are shown in Fig. 2a and b. Statistically significant improvements from baseline were observed in PASI (mean change − 4.9; 95% CI − 5.4, − 4.3) and BSA (mean change − 7.5; 95% CI − 8.5, − 6.4). There were statistically significant improvements in all patient-reported outcomes: patient-reported itch (mean change − 22.2; 95% CI − 24.9, − 19.5), skin pain (mean change − 15.5; 95% CI − 18.0, − 13.0), fatigue (mean change − 9.7; 95% CI − 11.8, − 7.6), EQ-5D health status (mean change 5.4; 95% CI 4.0, 6.9), and DLQI (mean change − 3.5; 95% CI − 4.0, − 3.0). Among the subset of patients with psoriatic arthritis, there were statistically significant improvements in joint pain due to psoriatic arthritis (mean change − 17.6; 95% CI − 20.8, − 14.5) and PGA (mean change − 18.3; 95% CI − 21.5, − 15.2).
Outcomes at 6 months for the dichotomous measures are shown in Fig. 2c. Among the 741 patients with PASI, 54%, 41%, and 31% achieved PASI75, PASI90, and PASI100, respectively. Over 72% of patients maintained or achieved PASI ≤ 3. Similarly, 74% of patients maintained or achieved BSA ≤ 3% or experienced at least 75% improvement in BSA, and 54% of patients maintained or achieved BSA ≤ 1%. Half (50%) of patients maintained or achieved IGA 0/1, and 48% maintained or achieved DLQI 0/1.
3.3 Mean Changes from Baseline by Prior Biologic Class
3.3.1 Within-Group Changes
Among ixekizumab initiators switching from TNFi + IL-12/23i, there were statistically significant changes from baseline to 6 months in all disease activity and patient-reported outcomes after adjusting for a priori baseline covariates (PASI: mean change − 4.88; 95% CI − 5.30, − 4.47; BSA: mean change − 7.62; 95% CI − 8.39, − 6.84; DLQI: mean change − 3.60; 95% CI − 4.09, − 3.10; EQ-5D health status: mean change 5.64; 95% CI 3.96, 7.31; itch: mean change − 23.29; 95% CI − 26.22, − 20.36; skin pain: mean change − 16.73; 95% CI − 19.21, − 14.25; and fatigue: mean change − 10.75; 95% CI − 13.15, − 8.35) (OSM Table 2). Among the subset of patients with psoriatic arthritis, there were statistically significant changes in joint pain (mean change − 18.99; 95% CI − 22.69, − 15.29) and PGA (mean change − 19.40; 95% CI − 23.04, − 15.77).
Among those switching from non-ixekizumab IL-17i, there were statistically significant changes from baseline to 6 months in all disease activity and patient-reported outcomes after adjusting for a priori baseline covariates (PASI: mean change − 4.48; 95% CI − 5.03, − 3.93; BSA: mean change − 6.83; 95% CI − 7.86, − 5.81; DLQI: mean change − 3.25; 95% CI − 3.90, − 2.61; EQ-5D health status: mean change 6.20; 95% CI 4.01, 8.39; itch: mean change − 19.57; 95% CI − 23.41, − 15.73, skin pain: mean change − 14.10; 95% CI − 17.35, − 10.84; and fatigue: mean change − 8.76; 95% CI − 11.91, − 5.60) (OSM Table 3). Among the subset of patients with psoriatic arthritis, there were statistically significant changes in joint pain (mean change − 17.78; 95% CI − 22.72, − 12.85) and PGA (mean change − 18.64; 95% CI − 23.49, − 13.78).
Among ixekizumab initiators switching from IL-23i, there were statistically significant changes from baseline to 6 months in most disease activity and patient-reported outcomes after adjusting for a priori baseline covariates (PASI: mean change − 5.19; 95% CI − 6.02, − 4.36; BSA: mean change − 7.81; 95% CI − 9.34, − 6.27; DLQI: mean change − 3.37; 95% CI − 4.35, − 2.39; itch: mean change − 22.20; 95% CI − 28.03, − 16.38; skin pain: mean change − 12.83; 95% CI − 17.76, − 7.90; and fatigue: mean change − 7.78; 95% CI − 12.58, − 2.97). The exception was EQ-5D health status (mean change 1.95; 95% CI − 1.38, 5.28) (OSM Table 4). Among the subset of patients with psoriatic arthritis, there were statistically significant changes in joint pain (mean change − 12.48; 95% CI − 20.12, − 4.83) and PGA (mean change − 14.32; 95% CI − 21.83, − 6.81).
3.3.2 Between-Group Changes
In the unadjusted models, patients who switched to ixekizumab from a TNFi or IL-12/23i had larger mean changes in all observed outcomes relative to patients who switched to ixekizumab from a prior non-ixekizumab IL-17i or IL-23i. Statistically significant differences were observed across the three prior biologic groups for mean changes from baseline in PASI, BSA, EQ-5D health status, itch, and skin pain (all p-values < 0.05, data not shown).
When adjusting for patient age, gender, race, psoriasis duration, psoriatic arthritis, line of therapy and the baseline value of the outcome, there were no statistically significant between-group differences in the continuous outcomes at 6 months (Fig. 3a and b). Adjusted mean change in disease activity measures of PASI (− 4.5 vs. − 4.9 vs. − 5.2) and BSA (− 6.8 vs. − 7.6 vs. − 7.8) were similar between prior non-ixekizumab IL-17i, TNFi or IL-12/23i and IL-23i groups, respectively. Likewise, adjusted mean change in patient-reported outcomes of itch (− 19.6 vs. − 23.3 vs. − 22.2), skin pain (− 14.1 vs. − 16.7 vs. − 12.8) and fatigue (− 8.8 vs. − 10.8 vs. − 7.8) were similar between prior non-ixekizumab IL-17i, TNFi or IL-12/23i and IL-23i groups, respectively.
Among patients with psoriatic arthritis, there were no statistically significant between-group differences in unadjusted or adjusted mean changes in joint pain or PGA. Changes in joint pain were numerically slightly larger for patients with prior non-ixekizumab IL-17i or prior TNFi or IL-12/23i than for patients with prior IL-23i.
3.4 Likelihood of Response Compared to Prior Non-Ixekizumab IL-17i Group
In unadjusted modified Poisson regression models comparing likelihood of achieving dichotomous response outcomes at 6 months in the prior TNFi or IL-12/23i and IL-23i groups versus the non-ixekizumab IL-17i group, patients in the prior TNFi or IL-12/23i group had an increased likelihood of achieving disease severity response (PASI75: RR 1.18; 95% CI 1.01, 1.38; PASI90: RR 1.34; 95% CI 1.08, 1.65; PASI100: RR 1.37; 95% CI 1.05, 1.79; and IGA 0/1: RR 1.27; 95% CI 1.07, 1.52; data not shown). Additionally, patients in the prior IL-23i group had an increased likelihood of achieving disease severity response (PASI90: RR 1.40; 95% CI 1.07, 1.85; PASI100: RR 1.61; 95% CI 1.16, 2.25; and IGA 0/1: RR 1.35; 95% CI 1.07, 1.70; data not shown).
Adjustment for age, gender, race, psoriasis duration, psoriatic arthritis, line of therapy (one prior vs. two+ prior biologics) and baseline outcome yielded similar results to the unadjusted models. In the adjusted models (Fig. 4), there were statistically significant differences between groups with the prior TNFi or IL-12/23i group more likely to achieve PASI100 (RR 1.31; 95% CI 1.01, 1.69) and IGA 0/1 (RR 1.32; 95% CI 1.11, 1.57) and the prior IL-23i group more likely to achieve PASI90 (RR 1.45; 95% CI 1.10, 1.91), PASI100 (RR 1.55; 95% CI 1.12, 2.13), and IGA 0/1 (RR 1.39; 95% CI 1.12, 1.73) compared to the prior non-ixekizumab IL-17i group. There were no statistically significant between-group differences in achievement of PASI75, PASI ≤ 3, BSA ≤ 3% or ≥ 75% improvement, BSA ≤ 1%, or DLQI 0/1.
3.5 Factors Associated with PASI75 and DLQI 0/1
Factors positively associated with achieving PASI75 in the adjusted multivariable model included psoriatic arthritis (RR 1.35; 95% CI 1.18, 1.55), higher baseline PASI (RR 1.02; 95% CI 1.02, 1.03) and months between ixekizumab initiation and 6-month visit (RR 1.17; 95% CI 1.13, 1.22), whereas female patients were less likely to achieve PASI75 (RR 0.85; 95% CI 0.75, 0.97) (OSM Table 5).
Factors positively associated with maintaining or achieving DLQI 0/1 in the adjusted multivariable model included months between ixekizumab initiation and 6-month visit (RR 1.18; 95% CI 1.13, 1.24), whereas non-White race (RR 0.71; 95% CI 0.56, 0.89), current smoking (RR 0.81; 95% CI 0.65, 1.00), having psoriasis in high impact sites (RR 0.81; 95% CI 0.70, 0.93), and higher baseline DLQI (RR 0.96; 95% CI 0.94, 0.97) were associated with lower likelihood of achieving DLQI 0/1 (OSM Table 6). Prior biologic class was not significantly associated with achieving either PASI75 or DLQI 0/1 in the final adjusted models.
4 Discussion
This study identified improvements in disease severity and patient-reported outcomes at 6 months in real-world settings in patients with psoriasis who switched to ixekizumab after discontinuing another biologic. Compared to patients making intra-class switches from another IL-17i, patients switching class from a TNFi or IL-12/23i were more likely to achieve PASI100 and IGA 0/1, and patients switching class from an IL-23i were more likely to achieve PASI90 in addition to PASI100 and IGA 0/1. Other improvements were consistent regardless of prior biologic class.
Effectiveness of ixekizumab has been demonstrated in real-world settings [20,21,22]. Our updated findings for switching to ixekizumab are consistent with those of our earlier study [8], in which patients who switched to ixekizumab from any biologic other than the IL-17i secukinumab (i.e., TNFi, IL-12/23i, or IL-23i) had greater likelihood of achieving PASI75, PASI90, PASI100, IGA 0/1, and BSA ≤ 3% compared to those switching from secukinumab. This consistency is logical given that patients from the earlier study were also included in the present study. A more recent observational study in the Czech BIOREP registry showed treatment success in intra-class IL-17i switching at 24 weeks [23], while a systematic review and meta-analysis demonstrated that prior IL-17i exposure does not appear to impact effectiveness of another IL-17i [24]. Indeed, the IL-17i brodalumab was found to be effective in patients who failed other IL-17is [25]. By contrast, a longer-term study found low drug survival of brodalumab at 50 weeks after switching from ixekizumab [3]. These studies, however, did not compare patients switching within the IL-17i class to those switching from other classes.
Given the more recent entrance to the market of the IL-23i class and limited information on switching class from an IL-23i to an IL-17i, we were particularly interested in the patients who switched to ixekizumab from an IL-23i. In the small study by Mastorino and colleagues, five of seven patients who switched to an IL-17i after treatment failure with an IL-23i achieved PASI100 at 28 weeks and three of seven achieved PASI100 at 40 weeks [7]. The findings in our larger patient population, which included patients who switched regardless of reason, affirm these with statistically significant changes from baseline in most disease activity and patient-reported outcomes at 6 months. As the IL-23i class gains popularity, our results suggest that ixekizumab may be a good option for switching after IL-23i discontinuation.
Conversely, emerging evidence from a phase 3b open-label single-arm trial suggests that the IL-23i risankizumab may improve psoriasis response and symptoms for up to 1 year in patients who had suboptimal response to secukinumab or ixekizumab [26]. However, over 60% of patients in the open-label trial had switched from secukinumab, and treatment response in the open-label trial was lower than in the original IMMhance trial of risankizumab in which only 26% of patients had prior IL-17i use [27]. This follows a prior report of effectiveness of TNFi and IL-12/23i in patients with non-response to secukinumab [28] and small studies that have shown benefits of intra-class IL-23i switches [29, 30]. Future studies will be needed to confirm these findings in larger real-world patient populations and to determine patient characteristics associated with success within and between classes.
4.1 Limitations and Strengths
Limitations of the study include that the CorEvitas registry consists of a sample of adults with psoriasis who are not necessarily representative of all adults with psoriasis in the USA and Canada. In particular, these patients have attended at least two clinical visits with dermatologists. In addition, history of medication use prior to enrollment is derived from reports by patients and their current dermatologists within the registry. Given that IL-23i are the newest class of medications included in the study, there are fewer patients who switched from IL-23i than from the other classes. It is worth noting that the reasons for switching therapeutic classes varied, and not all patients reported a reason. Similarly, the reason for each visit is not captured, although the assumption can likely be made that the dermatology visit is related to psoriasis. The registry captures physician-reported prescribing without measures of patient adherence. Further, our findings are subject to limitations inherent in all observational studies, including the potential for unmeasured confounding and unknown patient factors linked to healthcare access.
Nevertheless, the study also has many strengths resulting from the CorEvitas Psoriasis Registry, a longitudinal prospective registry collecting data from both patients and providers on psoriasis treatment and a wide range of both physician- and patient-reported disease outcomes. This provides a unique resource of large sample size, and longitudinal follow-up on the real-world use of biologic drugs in the USA and Canada. The registry enables examination of response patterns based on measures relevant to patient-physician encounters and a large set of patient histories and characteristics to use as predictors of response. Moreover, the registry contains clinical data (e.g., disease activity scores and patient-reported outcomes data) that are not available in claims databases.
5 Conclusions
These updated findings with IL-23i data reaffirm that real-world patients with psoriasis who switch to ixekizumab after discontinuing another biologic demonstrate improvements in disease severity and patient-reported outcomes at 6-month follow-up. These improvements were largely similar irrespective of the immediate prior biologic class; however, patients who switched class (from a TNFi or IL-12/23i, or IL-23i) were more likely to achieve response for some dichotomous disease severity outcomes compared to patients who switched from a prior IL-17i. In our regression analysis, we did not find that PASI75 and DLQI 0/1 were impacted by prior biologic class. The results advance the evidence base for offering patients a holistic, personalized approach to psoriasis management by tailoring treatment to patient needs [31,32,33]. Further research in real-world data sources is needed to evaluate the persistence of ixekizumab response long term after switching from other biologics.
References
Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–72.
Honda H, Umezawa Y, Kikuchi S, Yanaba K, Fukuchi O, et al. Switching of biologics in psoriasis: reasons and results. J Dermatol. 2017;44(9):1015–9.
Bethlem JC, Janssens JAHM, Tijoe M. Real-world survival of brodalumab, in patients with psoriasis switched from ixekizumab: results of a single centre retrospective study (BroSwitch). J Eur Acad Dermatol Venereol. 2023;2(3):510–7.
Gottlieb AB, Lacour JP, Korman N, Wilhelm S, Dutronc Y, et al. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two phase III randomized studies. J Eur Acad Dermatol Venereol. 2017;31(4):679–85.
Deza G, Norario J, Lopez-Ferrer A, Vilarrasa E, Ferran M, et al. Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study. J Eur Acad Dermatol Venereol. 2019;33(3):553–9.
Chiricozzi A, Burlando M, Caldarola G, Conti A, Damiani G, et al. Ixekizumab effectiveness and safety in the treatment of moderate-to-severe plaque psoriasis: a multicenter, retrospective observational study. Am J Clin Dermatol. 2020;21(3):441–7.
Mastorino L, Roccuzzo G, Dapavo P, Siliquini N, Avallone G, et al. Switching from IL-23 inhibitors to IL-17 inhibitors: a safe and effective practice? Dermatol Ther. 2022;35(9): e15697.
Lockshin B, Harrison RW, McLean RR, Crabtree MM, Konicek BW, et al. Outcomes in ixekizumab patients following exposure to secukinumab and other biologics in the CorEvitas Psoriasis Registry. Dermatol Ther. 2022;12:2797–815.
Warren RB, Marsden A, Tomenson B, Mason KJ, Soliman MM, et al. Identifying demographic, social, and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. Br J Dermatol. 2019;180(5):1069–76.
Schwartz CW, Loft N, Rasmussen MK, Nissen CV, Dam TN, et al. Predictors of response to biologics in patients with moderate-to-severe psoriasis: a Danish nationwide cohort study. Acta Derm Venereol. 2021;101(10): adv00579.
Strober B, Karki C, Mason M, Guo N, Holmgren SH, et al. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: results from the Corrona Psoriasis Registry. J Am Acad Dermatol. 2018;78(2):323–32.
Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician’s Global Assessment. J Am Acad Dermatol. 2004;51(4):563–9.
Spuls PI, Lecluse LL, Poulsen ML, Bos JD, Stern RS, Nijsten T. How good are clinical severity and outcome measures for psoriasis? Quantitative evaluation in a systematic review. J Invest Dermatol. 2010;130(4):933–43.
Langley RG, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5-point Investigator’s Global Assessment (IGA) scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat. 2015;26(1):23–31.
Armstrong AW, Siegel MP, Bagel J, Boh EE, Buell M, et al. From the Medical Board of the National Psoriasis Foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76(2):p290–8.
Scott PJ, Huskisson EC. Measurement of functional capacity with visual analogue scales. Rheumatol Rehabil. 1977;16(4):257–9.
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–6.
Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean? J Invest Dermatol. 2005;125(4):659–64.
Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159(7):702–6.
Megna M, Potestio L, Camela E, Fabbrocini G, Ruggiero A. Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: results from an Italian single-center retrospective study in a real-life setting. Dermatol Ther. 2022;35(9): e15667.
Mastorino L, Dapavo P, Burzi L, Rosset F, Giunipero di Corteranzo I, et al. Drug survival, effectiveness and safety of ixekizumab for moderate-to-severe psoriasis up to 5 years. J Eur Acad Dermatol Venereol. 2024;38(3):568–75.
Mastorino L, Cariti C, Susca S, Siliquini N, Verrone A, et al. Comparison between brodalumab, secukinumab and ixekizumab effectiveness and drug survival: a real-life experience on 638 patients with psoriasis. Exp Dermatol. 2023;32(9):1591–4.
Tichy M, Kojanova M, Velackova B, Dolezal T, Gkalpakiotis S, et al. Efficacy of switches within the class of IL-17 inhibitors: an analysis of data from the Czech nationwide registry of psoriatic patients receiving biological/targeted therapy (BIOREP). Dermatol Ther. 2022;35(10): e15772.
Loft N, Halling AS, Egeberg A, Skov L. Efficacy of a second interleukin 17 inhibitor in patients with psoriasis: a systematic review and meta-analysis. J Am Acad Dermatol. 2021;84(1):130–8.
Kimmel G, Chima M, Kim HJ, Bares J, Yao CJ, et al. Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed. J Am Acad Dermatol. 2019;81(3):857–9.
Crowley J, Hong CH, Gooderham M, Kokolakis G, Photowala H, et al. 44102 Risankizumab efficacy for moderate-to-severe plaque psoriasis over 256 weeks in patients with prior biologic treatments. J Am Acad Dermatol. 2023;89(3 suppl):AB82.
Blauvelt A, Leonardi CL, Gooderham M, Papp KM, Philipp S, et al. Efficacy and safety of continuous risankizumab therapy vs. treatment withdrawal in patients with moderate to severe plaque psoriasis. JAMA Dermatol. 2020;156(6):1–11.
Damiani G, Conic RRZ, de Vita V, Costanzo A, Regazzini R, et al. When IL-17 inhibitors fail: real-life evidence to switch from secukinumab to adalimumab or ustekinumab. Dermatol Ther. 2019;32(2): e12793.
Bagit A, Maliyar K, Georgakopoulos JR, Rankin B, Rimke A, et al. Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: a multicenter retrospective study of switching within the interleukin-23 inhibitor class. JAAD Int. 2023;12:136–8.
Hamm C, Ramsoondar N, McGillis M, Waugh M, Gooderham M, Giroux LL. The effectiveness of risankizumab following guselkumab failure in moderate-to-severe psoriasis patients: a retrospective study. J Cutan Med Surg. 2023. https://doi.org/10.1177/12034754231191458. (online ahead of print).
Camela E, Potestio L, Fabbrocini G, Pallotta S, Megna M. The holistic approach to psoriasis patients with comorbidities: the role of investigational drugs. Expert Opin Investig Drugs. 2023;32(6):537–52.
Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27–40.
Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80(1):43–53.
Acknowledgements
The CorEvitas Psoriasis Registry was developed in collaboration with the National Psoriasis Foundation (NPF). The authors would like to thank all the investigators, their clinical staff, and patients who participate in the CorEvitas Psoriasis Registry. Medical writing assistance was provided by Kelly Strutz, PhD, and editorial assistance was provided by Kayla Callahan, MS, and Megan Phillips, CCRC, of CorEvitas, LLC, and funded by Eli Lilly and Company.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This study was sponsored by CorEvitas, LLC, and the analysis was funded by Eli Lilly and Company. Access to study data was limited to CorEvitas, and CorEvitas statisticians completed all the analysis; all authors contributed to the interpretation of the results. CorEvitas has been supported through contracted subscription in the last two years by AbbVie, Amgen, Inc., Arena, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Eli Lilly and Company, Genentech, GSK, Janssen Pharmaceuticals, Inc., LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., and UCB S.A.
Conflict of Interest
ML: Employee of Mount Sinai and receives research funds from: Abbvie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Cara Therapeutics, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen Research & Development, LLC, Ortho Dermatologics, Pfizer, Sanofi-Regeneron, and UCB, and is a consultant for Almirall, AltruBio Inc., AnaptysBio, Apogee, Arcutis, Inc., AstraZeneca, Atomwise, Avotres Therapeutics, Brickell Biotech, Boehringer-Ingelheim, Bristol-Myers Squibb, Castle Biosciences, Celltrion, CorEvitas, Dermavant Sciences, EPI, Evommune, Inc., Forte Biosciences, Galderma, Genentech, Incyte, LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Sanofi-Regeneron, Seanergy, Strata, Takeda, Trevi, and Verrica. BS: Consultant (honoraria): AbbVie, Acelyrin, Alamar, Alumis, Almirall, Amgen, Arcutis, Arena, Aristea, Asana, Boehringer Ingelheim, Kangpu Pharmaceuticals, Bristol Myers Squibb, Capital One, Celltrion, CorEvitas, Dermavant, Imagenebio, Janssen, Leo, Eli Lilly, Maruho, Meiji Seika Pharma, Protagonist, Monte Carlo, Takeda, Novartis, Pfizer, UCB Pharma, Sun Pharma, Rapt, Regeneron, Sanofi-Genzyme,SG Cowen, Union Therapeutics, Ventyxbio, and vTv Therapeutics; Stock options: Connect Biopharma and Mindera Health; Speaker: AbbVie, Arcutis, Dermavant, Eli Lilly, Incyte, Janssen, Regeneron, and Sanofi-Genzyme; Scientific co-director (consulting fee): CorEvitas Psoriasis Registry; Investigator: CorEvitas Psoriasis Registry; Editor-in-Chief (honorarium): Journal of Psoriasis and Psoriatic Arthritis. AS, AHL, TE: CorEvitas employees; AHL: Eli Lilly stock. BZ, WNM, JB, MF: Eli Lilly employees/stock. AB: Speaker (received honoraria) for AbbVie, Eli Lilly and Company, Pfizer, and UCB; Scientific Adviser (received honoraria) for AbbVie, Abcentra, Aclaris, Affibody, Aligos, Almirall, Alumis, Amgen, Anaptysbio, Apogee, Arcutis, Arena, Aslan, Athenex, Bluefin Biomedicine, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, CTI BioPharma, Dermavant, EcoR1, Eli Lilly and Company, Escient, Evelo, Evommune, Forte, Galderma, HighlightII Pharma, Incyte, InnoventBio, Janssen, Landos, Leo, Lipidio, Microbion, Merck, Monte Rosa Therapeutics, Nektar, Novartis, Overtone Therapeutics, Paragon, Pfizer, Q32 Bio, Rani, Rapt, Regeneron, Sanofi Genzyme, Spherix Global Insights, Sun Pharma, Takeda, TLL Pharmaceutical, TrialSpark, UCB Pharma, Union, Ventyx, Vibliome, and Xencor; and Clinical Study Investigator (institution has received clinical study funds) for AbbVie, Acelyrin, Allakos, Almirall, Alumis, Amgen, Arcutis, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Concert, Dermavant, Eli Lilly and Company, Evelo, Evommune, Galderma, Incyte, Janssen, Leo, Merck, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, UCB Pharma, and Ventyx.
Availability of Data and Materials
Data are available from CorEvitas, LLC, through a commercial subscription agreement and are not publicly available. No additional data are available from authors.
Ethics Approval
The study was performed in accordance with the Declaration of Helsinki and the Guidelines for Good Pharmacoepidemiology Practice (GPP). All participating investigators were required to obtain full board approval for conducting noninterventional research involving human subjects with a limited dataset. Sponsor approval and continuing review was obtained through a central Institutional Review Board (IRB; Advarra, Protocol number Pro00051221). For academic investigative sites that did not receive a waiver to use the central IRB, full board approval was obtained from the respective governing IRBs and documentation of approval was submitted to CorEvitas, LLC, prior to the initiation of any study procedures.
Consent to participate
All patients in the registry were required to provide written informed consent and authorization prior to participating.
Author Contributions
The authors confirm contribution to the paper as follows: study conception or design: ML, AS, AHL, BZ, WNM, JB; data acquisition, analysis, or interpretation of results: ML, BS, AS, AHL, TE, BZ, WNM, JB, AB; manuscript drafting or critical revision for important content: ML, BS, AS, AHL, TE, BZ, WNM, JB, AB. All authors read and approved the final version.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Lebwohl, M., Strober, B., Schrader, A. et al. Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry. Drugs - Real World Outcomes 11, 451–464 (2024). https://doi.org/10.1007/s40801-024-00439-w
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40801-024-00439-w